FLT3 inhibitors in the management of acute myeloid leukemia

Zappone, Elisabetta; Defina, Marzia; Aprile, Lara; Gozzetti, Alessandro; Bartalucci, Giulia; Bocchia, Monica

CINECA IRIS Institutional Research Information System

IRIS è la soluzione IT che facilita la raccolta e la gestione dei dati relativi alle attività e ai prodotti della ricerca. Fornisce a ricercatori, amministratori e valutatori gli strumenti per monitorare i risultati della ricerca, aumentarne la visibilità e allocare in modo efficace le risorse disponibili.

In recent years there has been a great improvement in molecular characterization of acute myeloid leukemia (AML) allowing the stratification of patients in different rate of risk. Patients with FLT3 mutated AML have poor prognosis because of resistance to induction chemotherapy or early relapse. Several first and second generation molecules, able to inhibit FLT3 signaling have been developed and many single agent or combination studies are ongoing. Of these, quizartinib seems to have the best clinical activity. Unfortunately, resistance to FLT3 inhibitors have been observed and many scientists are currently investigating new strategy to restore sensitivity to FLT3 inhibitors.

Scheda prodotto non validato

Scheda prodotto in fase di analisi da parte dello staff di validazione

Titolo:	FLT3 inhibitors in the management of acute myeloid leukemia
Autori:	Zappone, Elisabetta Defina, Marzia APRILE, LARA GOZZETTI, ALESSANDRO Bartalucci, Giulia BOCCHIA, MONICA mostra contributor esterni nascondi contributor esterni
Anno:	2016
Rivista:	ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
Abstract:	In recent years there has been a great improvement in molecular characterization of acute myeloid leukemia (AML) allowing the stratification of patients in different rate of risk. Patients with FLT3 mutated AML have poor prognosis because of resistance to induction chemotherapy or early relapse. Several first and second generation molecules, able to inhibit FLT3 signaling have been developed and many single agent or combination studies are ongoing. Of these, quizartinib seems to have the best clinical activity. Unfortunately, resistance to FLT3 inhibitors have been observed and many scientists are currently investigating new strategy to restore sensitivity to FLT3 inhibitors.
Handle:	http://hdl.handle.net/11365/1006961
Appare nelle tipologie:	1.1 Articolo in rivista

File in questo prodotto:

Non ci sono file associati a questo prodotto.

Utilizza questo identificativo per citare o creare un link a questo documento:
http://hdl.handle.net/11365/1006961

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.